Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells
- Development stage
- Phase 1
- Lead developer
- Yohanes Firmansyah
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intracutaneous
01
Overview
Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) is a cell-free biological therapy derived from the secretome of mesenchymal stem cells found in the Wharton's jelly of the human umbilical cord. This conditioned medium contains a complex mixture of paracrine factors, including growth factors, cytokines, and extracellular vesicles (exosomes), which facilitate tissue repair and regeneration. Developed by Yohanes Firmansyah, it is primarily being investigated for the treatment of chronic trophic ulcers, particularly those associated with leprosy that are resistant to conventional treatments. The therapy aims to promote wound healing by stimulating granulation tissue growth and reducing inflammation (edema and erythema) through intracutaneous administration.
- Other names
- Human umbilical cord secretomeSecretomeCM-WJMSC
Beyond the preview
Go deeper on Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells.